Australian biotech market watch 11/11/09

By Tim Dean
Wednesday, 11 November, 2009

Amongst the biggest winners today is Biota Holdings (ASX:BTA), up 7c to $2.78, after seeing fluctuating prices over the last couple of weeks.

Pharma company, ChemGenex (ASX:CXS), gained 3c to 91c, on the back of news of the FDA granding Priority Review status to its anti-leukaemia drug, Omapro, earlier this week.

CSL (ASX:CSL) is also up, lifting 1.5% to $32.30, recovering the losses it experienced throughout October.

Falls were experienced by pSividia (ASX:PVA), which dropped 10% to $3.23 in moderate trading, and Patrys (ASX:PAB), which this morning announced the awarding of a grant to researchers collaborating on one of its anti-cancer treatments, fell 1c to 16c.

Blackmores (ASX:BKL) dropped 40c to $20.80, and ResMed (ASX:RMD), lost 5c to $5.27. Cochlear (ASX:COH) also fell by 51c to $62, down by 0.82%.

The All Ordinaries has experienced its fourth consecutive day of gains, up 19.5 points to 4,763.5 as of 4pm this afternoon, mainly on the back of property trusts.

Related News

Anti-inflammatory agent could decrease septic shock mortality

Researchers have discovered a naturally occurring blood protein — a type of...

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd